Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Partnership between small biotech and big pharma.

Gregory J Wiederrecht1, Raymond G Hill, Margaret S Beer

  • 1Merck & Co Inc, Rahway, NJ 07065-0900, USA.

Idrugs : the Investigational Drugs Journal
|July 28, 2006
PubMed
Summary

Big pharma faces challenges in drug discovery due to complexity and new demands. Merck & Co. is increasing partnerships with biotech and academic institutions to develop novel medicines for unmet needs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Task-related differences in network connectivity and dynamics in people with severe opioid use disorder compared with healthy controls.

Translational psychiatry·2026
Same author

Understanding the UK Psychoactive Substances Act.

British journal of clinical pharmacology·2019
Same author

Bioscience industry: opportunities for early career researchers.

Lancet (London, England)·2015
Same author

New treatments for neuropathic pain.

Annual review of medicine·2006
Same author

Aminoalkyl phenyl sulfones--a novel series of 5-HT7 receptor ligands.

Bioorganic & medicinal chemistry letters·2005
Same author

Native and recombinant human Edg4 receptor-mediated Ca(2+) signalling.

Assay and drug development technologies·2004

Area of Science:

  • Pharmaceutical Sciences
  • Drug Discovery and Development
  • Biotechnology

Background:

  • Big pharma's traditional drug discovery models are evolving.
  • Increased complexity of diseases and stringent regulatory/investor demands are key drivers.
  • Biotech companies now possess advanced drug discovery tools and capabilities.

Purpose of the Study:

  • To examine Merck & Co. Inc.'s strategy in partnering with biotech and academic institutions.
  • To understand how these collaborations enhance the identification of novel medicines.
  • To focus on unmet medical needs in specific therapeutic areas.

Main Methods:

  • Analysis of Merck & Co. Inc.'s historical reliance on internal research and licensing.
  • Examination of the company's strategic shift towards external collaborations.
  • Identification of therapeutic areas targeted for partnership and internal development.

Main Results:

  • Biotech companies are significant players in identifying drug leads and potential medicinal products.
  • Diversification in drug discovery has led to increased partnerships between biotech and big pharma.
  • Merck & Co. is actively engaging in collaborations to improve success rates in novel drug identification.

Conclusions:

  • Strategic partnerships are crucial for big pharma to address complex diseases and unmet needs.
  • Merck & Co.'s collaborative approach aims to enhance its pipeline in critical therapeutic areas.
  • The evolving landscape of drug discovery necessitates integrated strategies involving internal R&D and external innovation.

Related Experiment Videos